

What's new for trauma haemorrhage management?

ABSTRACT

Uncontrolled haemorrhage is the leading cause of preventable death from injury and is a major contributor to the global burden of disease. The majority of deaths resulting from bleeding occur within the first 3 hours of hospital admission, and the window for meaningful intervention is therefore extremely small. Resuscitative efforts during active bleeding should focus on maintaining haemostatic function with blood product transfusion and early administration of tranexamic acid. Achieving control of haemorrhage is the overarching treatment priority and may require temporising measures before definitive surgical or radiological intervention. This review summarizes the contemporary approaches to resuscitation of bleeding trauma patients, options for achieving haemorrhage control, and current areas of active research including organ protective resuscitation and suspended animation.

Physical injuries are a leading cause of death and disability worldwide. An estimated 1 billion injuries requiring health care occur each year, accounting for around 5 million deaths and 10% of the total global burden of disease (GBD 2016 Causes of Death Collaborators, 2017). Uncontrolled haemorrhage is the leading cause of preventable death from injury, the majority of which cases occur within the first 3 hours of hospital admission (Bardes et al, 2018). Modern trauma systems and resuscitation practices have therefore evolved to prioritize early definitive haemorrhage control while supporting haemostasis during active bleeding.

This review summarizes current approaches to the management of traumatic haemorrhage, with reference to the National Institute for Health and Care Excellence (2016) guidelines for the management of major trauma. It discusses the principles and practicalities of resuscitation during active bleeding, current strategies to achieve temporary and definitive haemorrhage control, and future directions for organ preservation during and after massive bleeding.

Mr Paul Vulliamy, Clinical Lecturer and Specialist Registrar in General Surgery, Centre for Trauma Sciences, Blizard Institute, Queen Mary University of London, London

Mr Anthony J Thaventhiran, Clinical Research Fellow and Specialist Registrar in General Surgery, Centre for Trauma Sciences, Blizard Institute, Queen Mary University of London, London

Mr Ross A Davenport, Consultant Surgeon and Senior Lecturer, Centre for Trauma Sciences, Blizard Institute, Queen Mary University of London, London E1 2AT

Correspondence to: Mr RA Davenport
(r.a.davenport@qmul.ac.uk)

Resuscitation of the bleeding trauma patient

Permissive hypotension

Avoiding rapid normalization of blood pressure during active bleeding is known as permissive hypotension. This strategy, first described during World War I, works on the principle that increases in blood pressure risk 'popping the clot' and therefore inducing further bleeding. The finding that early aggressive fluid resuscitation in patients with penetrating trauma results in increased mortality has led to the widespread incorporation of permissive hypotension into trauma resuscitation protocols (Bickell et al, 1994). Although there is solid pre-clinical evidence for this approach, clinical data are equivocal (Morrison et al, 2011; Carrick et al, 2016). A restrictive volume replacement strategy is recommended in patients with haemorrhagic shock during active bleeding, but caution should be exercised in patients with a suspected concomitant brain injury in order to maintain adequate cerebral perfusion pressure.

Trauma-induced coagulopathy

Up to a quarter of all severely injured patients have impaired haemostatic function by the time of arrival in hospital (Brohi et al, 2003). This state, termed acute traumatic coagulopathy, develops within minutes of injury as an endogenous response to tissue damage and shock, and is characterized by a reduction in clot strength coupled with excessive clot breakdown (Davenport et al, 2011). It is associated with persistent uncontrolled bleeding, increased transfusion requirements and a four-fold higher mortality (Davenport et al, 2011). Efforts at resuscitation can add to this coagulopathy by causing dilution, acidaemia and hypothermia. Trauma-induced coagulopathy is therefore a complex, multifactorial condition with both endogenous and iatrogenic elements. The pathophysiology and diagnosis of this state have been discussed in detail elsewhere (Davenport and Brohi, 2016). For the clinician managing major bleeding in the injured patient, awareness of acute traumatic coagulopathy and trauma-induced coagulopathy is essential to prioritize appropriate therapy during active haemorrhage.

Balanced resuscitation

Balanced or haemostatic resuscitation is the principle of supporting haemostasis while bleeding is ongoing with the empiric provision of blood and blood products. A central component of this practice is administration of high volumes of fresh frozen plasma and platelet concentrates alongside packed red blood cells. This practice is supported

Table 1. Summary of National Institute for Health and Care Excellence (2016) guidelines for the resuscitation of traumatic haemorrhage

Use a trauma-specific major haemorrhage protocol
Use a restrictive volume strategy during active bleeding unless major traumatic brain injury is present
Do not give crystalloids or colloids during active haemorrhage in hospital
Start with a fixed ratio of blood products – aim for 1:1:1 fresh frozen plasma:platelets:packed red blood cells
Use laboratory and/or point of care testing to guide subsequent resuscitation
Give tranexamic acid to bleeding patients as early as possible but avoid if >3 hours post-injury
Prioritize early definitive haemorrhage control

From National Institute for Health and Care Excellence (2016)

by a number of cohort studies and by the PROPPR randomized trial, which found reduced deaths as a result of haemorrhage in patients treated with a 1:1:1 ratio of fresh frozen plasma:platelets:packed red blood cells compared to a 1:1:2 ratio (Holcomb et al, 2015; Balvers et al, 2017). Early initiation of a fixed ratio 1:1:1 resuscitation strategy is recommended by the National Institute for Health and Care Excellence (2016) guidelines (*Table 1*). Crystalloid infusion results in a dilutional coagulopathy and is associated with worse outcomes when given during active haemorrhage (Neal et al, 2012). It should be avoided in the in-hospital setting, and only given in small volumes in the prehospital setting to patients in extremis to maintain a palpable central pulse.

It is essential that all hospitals managing trauma patients have an established major haemorrhage protocol (National Institute for Health and Care Excellence, 2016). Activation of this protocol should be based on the patient's injury profile and dynamic assessment of his/her haemodynamic status. This protocol should deliver packs containing a fixed ratio of packed red blood cells and other blood components. Blood product transfusion should be instituted empirically in trauma patients with evidence of bleeding and not deferred until blood results are available, although laboratory results can be used to guide ongoing resuscitation when they are available (Hunt et al, 2015).

Fibrinogen

Fibrinogen is the essential substrate for clot formation. Conversion of fibrinogen to cross-linked fibrin strands is the end point of the coagulation cascade and forms the basis of a stable clot. Depletion of fibrinogen is a characteristic feature of acute traumatic coagulopathy, and hypofibrinogenaemia is strongly associated with mortality in trauma patients (Rourke et al, 2012). However, the evidence for appropriate fibrinogen replacement therapies in bleeding trauma patients is less clear than that for fresh frozen plasma and platelet transfusion.

In the UK, cryoprecipitate is the standard therapy to replace fibrinogen in bleeding patients, but is typically not prioritized in major haemorrhage protocol delivery and

therefore not given until several hours after patients arrive at the major trauma centre (Stanworth et al, 2016). In the CRYOSTAT trial, a phase II randomized controlled trial at a single major trauma centre in the UK, early high-dose cryoprecipitate was effective in maintaining fibrinogen levels during active haemorrhage compared to standard care (Curry et al, 2015). The impact of early cryoprecipitate on survival is currently being evaluated in CRYOSTAT-2, a multicentre trial which is currently recruiting at all major trauma centres in England (Marsden et al, 2019). Until the evidence from this trial is available, current treatment regimens should include fibrinogen supplementation as part of the major haemorrhage protocol.

Prehospital blood products

There is increasing interest in prehospital delivery of blood products in civilian trauma systems. In the UK, a number of prehospital services deliver packed red blood cells and, in some cases, fresh frozen plasma or lyophilised plasma at the roadside (Lyon et al, 2017; Oakeshott et al, 2018). The benefits of prehospital fresh frozen plasma have been demonstrated in the PAMPER trial, which found a 10% absolute reduction in mortality in severely injured patients receiving two units of fresh frozen plasma during prehospital transport compared to those receiving crystalloid (Sperry et al, 2018). The effect of pre-hospital packed red blood cell and lyophilised plasma transfusion on survival is being evaluated in the RePhILL study, which is currently recruiting at a number of air ambulance services across the UK (Smith et al, 2018).

Whole blood

The use of whole blood rather than component therapy has received renewed attention in recent years, more than half a century after it was widely used in World War II and the Korean War. There are several theoretical advantages to whole blood in bleeding patients: it enables delivery of red cells and haemostatic components of blood in the ratios in which they are lost, and it avoids the need for freeze–thaw cycles which may result in loss of haemostatic potential (Spinella and Cap, 2016). Cold-stored, leukodepleted red

“ The time from injury to haemorrhage control is a critical determinant of outcome. ”

cells and plasma are available through the NHS blood and transfusion service and are currently being evaluated by London's Air Ambulance in the pre-hospital phase as part of a feasibility study. It is important to note that this product does not contain platelets, which are lost during leukodepletion, and therefore is intended to supplement rather than replace a component-based approach. Work is in progress to develop a platelet-rich product with specialized filters (Remy et al, 2018).

Tranexamic acid

In addition to blood products, early administration of the antifibrinolytic agent tranexamic acid has become an important component of major haemorrhage protocols in much of the world since the publication of the landmark CRASH-2 trial (Shakur et al, 2010). The survival advantage conferred by tranexamic acid diminishes in a linear manner with increasing time from injury, and it should therefore be administered in the prehospital phase where possible, and ideally within 1 hour of injury (Gayet-Ageron et al, 2018). For reasons which remain unclear, tranexamic acid appears to increase mortality when given more than 3 hours after injury and should therefore be avoided when presentation is delayed.

Goal-directed resuscitation

Point-of-care viscoelastic tests such as TEG and ROTEM have been used extensively to profile post-traumatic alterations in haemostasis (Hagemo et al, 2015). These assays provide real-time quantification of different aspects of coagulation and yield meaningful results within 5 minutes of initiating the test. There is growing interest in whether these assays can be used to direct blood product transfusion and tranexamic acid administration based on alterations in clot initiation, clot strength and clot breakdown (Baksaas-Aasen et al, 2018). Although this approach has been adopted in some centres, high quality evidence from randomized trials is still awaited – this knowledge gap will be addressed by the multicentre iTACTIC (implementation of Treatment Algorithms for the Management of Trauma Induced Coagulopathy) trial which has completed recruitment and will report in the next year (Baksaas-Aasen et al, 2017).

Stopping the bleeding

Definitive haemorrhage control

All interventions delivered while haemorrhage is ongoing are temporising measures, and normal physiology cannot be restored until definitive control of bleeding is achieved. The overarching priority in care of the bleeding patient is therefore early definitive haemorrhage control. In most patients, this will require surgical or radiological intervention.

Damage control surgery is an operative strategy which prioritizes restoration of physiology over definitive anatomical reconstruction. In practice this means abbreviated procedures aimed at controlling bleeding and contamination. Examples are placement of temporary vascular shunts as opposed to definitive repairs, packing of major hepatic or pelvic injuries, and resection of injured bowel without restoring intestinal continuity. Temporary abdominal closure is routinely used in patients with haemorrhagic shock requiring laparotomy, as it prevents abdominal compartment syndrome and enables early re-evaluation of injuries. Once transferred to critical care, the goals of treatment are restoration of homeostasis to enable the patient to tolerate a planned re-look procedure after 24–48 hours. In combination with balanced resuscitation, this strategy has led to major improvements in clinical outcomes among bleeding trauma patients (Cotton et al, 2011).

Increasingly, radiological procedures have replaced (or supplemented) conventional surgical management of many injuries. Angio-embolisation for bleeding in the pelvis, liver and spleen are mainstays of therapy and obviate the need for major surgery, which spares the critically injured patient a major additional physiological insult. Endovascular procedures for major vascular injuries, most notably traumatic aortic dissection, have also become the standard of treatment. A combination of surgical and radiological techniques may improve outcomes in patients with complex injuries (Matsumoto et al, 2018).

Temporary haemorrhage control

The time from injury to haemorrhage control is a critical determinant of outcome. Adjunctive measures to provide temporary control of bleeding and enable transfer to a facility capable of delivering definitive care therefore have great potential to improve care of bleeding patients.

Resuscitative endovascular balloon occlusion of the aorta

Among the most widely discussed and debated of these adjunctive therapies is resuscitative endovascular balloon occlusion of the aorta (REBOA). This procedure involves placement of an occlusive balloon in either the abdominal or thoracic aorta via a femoral access sheath. This essentially provides a minimally invasive alternative to thoracotomy and aortic cross clamping, achieving the same effect of interrupting blood flow to bleeding sites distal to the balloon and increasing central perfusion.

Resuscitative endovascular balloon occlusion of the aorta is reserved for patients with exsanguinating torso haemorrhage and can be deployed either in hospital or pre-hospital (Sadek et al, 2016). The clearest indication for resuscitative endovascular balloon occlusion of the aorta is major bleeding from pelvic fractures, in which scenario the balloon is inflated in the infra-renal aorta (zone 3). Balloon deployment in the thoracic aorta (zone 1) is also being

Continued on p. 271

Continued from p. 270

increasingly used in traumatic cardiac arrest secondary to uncontrolled intra-abdominal haemorrhage. All patients undergoing resuscitative endovascular balloon occlusion of the aorta need careful post-procedural care to mitigate the risks of limb ischaemia and the systemic complications of ischaemia-reperfusion syndrome.

Advocates of resuscitative endovascular balloon occlusion of the aorta point to a number of retrospective cohort studies which suggest a survival benefit when compared to resuscitative thoracotomy (Moore et al, 2016). However, critics have voiced concerns regarding ischaemic complications of prolonged balloon occlusion times, local complications associated with femoral sheath placement, and the potential for inappropriate deployment in non-bleeding patients (Saito et al, 2015). There is currently a lack of level one evidence to support either perspective, a knowledge gap which is being addressed by the multicentre randomized UK-REBOA trial (Jansen et al, 2017).

Limb tourniquets

The use of tourniquets for control of extremity bleeding dates back at least to the 4th century BC. Although their use fell out of favour in modern civilian trauma care during the 20th century, the latest evidence suggests that tourniquets can reduce mortality from major limb bleeding without increasing the risk of amputation (Teixeira et al, 2018). In the UK, the National Institute for Health and Care Excellence (2016) guidelines recommend that tourniquets should be reserved only for major limb bleeding which cannot be controlled by direct pressure alone. Judicious patient selection is important to minimize the risks of ischaemic complications associated with prolonged tourniquet use, the tourniquet time should be accurately recorded and the total duration of use kept to a minimum.

Pelvic binders

Pelvic binders provide circumferential compression of the bony pelvis, providing emergency stabilization of a pelvic fracture and theoretically reducing blood loss. Observational studies suggest a survival benefit associated with their use (Bakhshayesh et al, 2016). The risks associated with binder application for short periods are minimal, but prolonged use should be avoided to prevent pressure-related complications. Current National Institute for Health and Care Excellence (2016) guidelines recommend applying a pelvic binder only in patients with haemodynamic instability and a suspected pelvic fracture.

Future directions

Despite major advances in the treatment of trauma-haemorrhage, it is important to recognize the limitations of contemporary resuscitation practices. Haemorrhage remains the dominant cause of preventable death from injury, and massive haemorrhage carries a mortality of around 50% (Stanworth et al, 2016; Bardes et al, 2018).

“ Judicious patient selection is important to minimize the risks of ischaemic complications associated with prolonged tourniquet use. ”

Outcomes in patients requiring damage control surgery for intra-abdominal haemorrhage have not improved significantly in the last decade (Harvin et al, 2017; Marsden et al, 2018). The moniker of haemostatic resuscitation may also be unfounded, as markers of shock and coagulopathy do not improve during active haemorrhage even if the core principles are adhered to (Khan et al, 2015). Because of this, there is increasing focus on novel strategies to improve survival after exsanguinating haemorrhage.

Emergency preservation and resuscitation

Induction of a period of ‘suspended animation’ has been proposed as a strategy to improve the dismal survival rates of traumatic cardiac arrest from haemorrhage. The most extensively investigated approach to achieving a period of metabolic arrest has been through the use of therapeutic hypothermia. This strategy, involving rapid cooling to a core temperature of 10°C by infusion of ice-cold saline into the thoracic aorta, can produce survival without neurological sequelae in otherwise fatal animal models of trauma haemorrhage (Alam et al, 2008). This approach is currently being evaluated in a prospective clinical trial of patients presenting with cardiac arrest from penetrating trauma (Tisherman et al, 2017).

Organ protective resuscitation

Multiple organ dysfunction syndrome is the major early sequela of trauma haemorrhage and contributes to much of the morbidity and mortality after the initial bleeding phase (Shepherd et al, 2017). Although there are currently no specific agents for the prevention and treatments of post-traumatic multiple organ dysfunction syndrome, this is an area of active investigation. Perhaps the most promising potential therapy is artesunate, a widely used antimalarial drug which has potent cytoprotective effects and attenuates organ dysfunction in a rodent model of haemorrhagic shock (Sordi et al, 2017). This is currently being evaluated in a phase II clinical trial of bleeding patients in which artesunate or placebo is given as a bolus within 4 hours of injury.

Novel strategies for haemorrhage control

In recognition of the fact that many bleeding patients currently exsanguinate before intervention, a number of novel strategies for temporary haemorrhage control are being investigated. These include a self-expanding haemostatic foam which can be injected into the abdominal cavity to tamponade bleeding. This has shown promise in large animal models of trauma haemorrhage and is currently being evaluated in a human trial (Rago et al, 2014; Chang et al, 2015). Abdominal and junctional tourniquets are another recent development with the aim of controlling proximal

KEY POINTS

- Rapid definitive control of bleeding by surgical and/or radiological interventions is the overarching treatment priority in patients with traumatic haemorrhage.
- Resuscitation during active haemorrhage should aim to support haemostatic function using a trauma-specific major haemorrhage protocol.
- Adjunctive temporising measures such as tourniquets, pelvic binders and resuscitative endovascular balloon occlusion of the aorta may be beneficial in selected patients.
- Clinical trials of novel treatment strategies including whole blood transfusion and organ protective resuscitation are currently ongoing.

limb and abdominal injuries, which have received particular attention from military trauma services (Smith et al, 2019). Further studies of their efficacy and safety are ongoing.

Conclusions

Haemorrhage after major injury remains a highly lethal condition and is a significant contributor to global morbidity and mortality. Rapid identification and definitive control of bleeding is the over-arching principle of management. Temporary measures to achieve haemorrhage control can be used to 'buy time' during transfer to definitive care. Resuscitation during active bleeding aims to maintain haemostatic competence and prevent dilutional coagulopathy by delivering high doses of blood components and pro-haemostatic agents such as tranexamic acid. Organ protection during resuscitation is an area of active investigation and is likely to play an increasing role in future treatment strategies. **BJHM**

Mr P Vulliamy was supported by a fellowship grant from the Royal College of Surgeons of England.

Conflict of interest: none.

- Alam HB, Duggan M, Li Y et al. Putting life on hold-for how long? Profound hypothermic cardiopulmonary bypass in a Swine model of complex vascular injuries. *J Trauma Inj Infect Crit Care*. 2008 Apr;64(4):912–922. <https://doi.org/10.1097/TA.0b013e3181659e7f>
- Bakshayesh P, Boutefnouchet T, Tötterman A. Effectiveness of non invasive external pelvic compression: a systematic review of the literature. *Scand J Trauma Resusc Emerg Med*. 2016 Dec;24(1):73. <https://doi.org/10.1186/s13049-016-0259-7>
- Baksaas-Aasen K, Gall L, Eaglestone S et al. iTACTIC – implementing Treatment Algorithms for the Correction of Trauma-Induced Coagulopathy: study protocol for a multicentre, randomised controlled trial. *Trials*. 2017 Dec;18(1):486. <https://doi.org/10.1186/s13063-017-2224-9>
- Baksaas-Aasen K, Van Dieren S, Balvers K et al; TACTIC/INTRN collaborators. Data-driven development of ROTEM and TEG algorithms for the management of trauma hemorrhage. *Ann Surg*. 2018 May 23. <https://doi.org/10.1097/SLA.0000000000002825>
- Balvers K, van Dieren S, Baksaas-Aasen K et al; Targeted Action for Curing Trauma-Induced Coagulopathy (TACTIC) Collaborators. Combined effect of therapeutic strategies for bleeding injury on early survival, transfusion needs and correction of coagulopathy. *Br J Surg*. 2017 Feb;104(3):222–229. <https://doi.org/10.1002/bjs.10330>
- Bardes JM, Inaba K, Schellenberg M et al. The contemporary timing of trauma deaths. *J Trauma Acute Care Surg*. 2018 Jun;84(6):893–899. <https://doi.org/10.1097/TA.0000000000001882>
- Bickell WH, Wall MJ Jr, Pepe PE, Martin RR, Ginger VF, Allen MK, Mattox KL. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. *N Engl J Med*. 1994 Oct 27;331(17):1105–1109. <https://doi.org/10.1056/NEJM199410273311701>

- Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. *J Trauma Inj Infect Crit Care*. 2003 Jun;54(6):1127–1130. <https://doi.org/10.1097/01.TA.0000069184.82147.06>
- Carrick MM, Morrison CA, Tapia NM et al. Intraoperative hypotensive resuscitation for patients undergoing laparotomy or thoracotomy for trauma. *J Trauma Acute Care Surg*. 2016 Jun;80(6):886–896. <https://doi.org/10.1097/TA.0000000000001044>
- Chang JC, Holloway BC, Zamisch M, Hepburn MJ, Ling GSF. ResQFoam for the treatment of non-compressible hemorrhage on the front line. *Mil Med*. 2015 Sep;180(9):932–933. <https://doi.org/10.7205/MILMED-D-15-00049>
- Cotton BA, Reddy N, Hatch QM et al. Damage control resuscitation is associated with a reduction in resuscitation volumes and improvement in survival in 390 damage control laparotomy patients. *Ann Surg*. 2011 Oct;254(4):598–605. <https://doi.org/10.1097/SLA.0b013e318230089e>
- Curry N, Rourke C, Davenport R et al. Early cryoprecipitate for major haemorrhage in trauma: a randomised controlled feasibility trial. *Br J Anaesth*. 2015 Jul;115(1):76–83. <https://doi.org/10.1093/bja/aev134>
- Davenport R, Manson J, De'Ath H et al. Functional definition and characterization of acute traumatic coagulopathy. *Crit Care Med*. 2011 Dec;39(12):2652–2658. <https://doi.org/10.1097/CCM.0b013e3182281af5>
- Davenport RA, Brohi K. Cause of trauma-induced coagulopathy. *Curr Opin Anaesthesiol*. 2016 Apr;29(2):212–219. <https://doi.org/10.1097/ACO.0000000000000295>
- Gayet-Ageron A, Prieto-Merino D, Ker K et al; Antifibrinolytic Trials Collaboration. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. *Lancet*. 2018 Jan;391(10116):125–132. [https://doi.org/10.1016/S0140-6736\(17\)32455-8](https://doi.org/10.1016/S0140-6736(17)32455-8)
- GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017 Sep;390(10100):1151–1210. [https://doi.org/10.1016/S0140-6736\(17\)32152-9](https://doi.org/10.1016/S0140-6736(17)32152-9)
- Hagemo JS, Christiaans SC, Stanworth SJ et al. Detection of acute traumatic coagulopathy and massive transfusion requirements by means of rotational thromboelastometry: an international prospective validation study. *Crit Care*. 2015 Dec;19(1):97. <https://doi.org/10.1186/s13054-015-0823-y>
- Harvin JA, Maxim T, Inaba K et al. Mortality after emergent trauma laparotomy. *J Trauma Acute Care Surg*. 2017 Sep;83(3):464–468. <https://doi.org/10.1097/TA.0000000000001619>
- Holcomb JB, Tilley BC, Baraniuk S et al; PROPPR Study Group. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. *JAMA*. 2015 Feb 03;313(5):471–482. <https://doi.org/10.1001/jama.2015.12>
- Hunt BJ, Allard S, Keeling D, Norfolk D, Stanworth SJ, Pendry K; British Committee for Standards in Haematology. A practical guideline for the haematological management of major haemorrhage. *Br J Haematol*. 2015 Sep;170(6):788–803. <https://doi.org/10.1111/bjh.13580>
- Jansen JO, Pallmann P, MacLennan G, Campbell MK; UK-REBOA Trial Investigators. Bayesian clinical trial designs: Another option for trauma trials? *J Trauma Acute Care Surg*. 2017 Oct;83(4):736–741. <https://doi.org/10.1097/TA.0000000000001638>
- Khan S, Davenport R, Raza I et al. Damage control resuscitation using blood component therapy in standard doses has a limited effect on coagulopathy during trauma hemorrhage. *Intensive Care Med*. 2015 Feb;41(2):239–247. <https://doi.org/10.1007/s00134-014-3584-1>
- Lyon RM, de Sausmarez E, McWhirter E et al; Kent, Surrey & Sussex Air Ambulance Trust. Pre-hospital transfusion of packed red blood cells in 147 patients from a UK helicopter emergency medical service. *Scand J Trauma Resusc Emerg Med*. 2017 Dec;25(1):12. <https://doi.org/10.1186/s13049-017-0356-2>
- Marsden M, Carden R, Navaratne L et al. Outcomes following trauma laparotomy for hypotensive trauma patients. *J Trauma Acute Care Surg*. 2018 May;85(3):1. <https://doi.org/10.1097/TA.0000000000001988>
- Marsden M, Benger J, Brohi K et al. Coagulopathy, cryoprecipitate and CRYOSTAT-2: realising the potential of a nationwide trauma system for a national clinical trial. *Br J Anaesth*. 2019

- Feb;122(2):164–169. <https://doi.org/10.1016/j.bja.2018.10.055>
- Matsumoto S, Cantrell E, Jung K, Smith A, Coimbra R. Influence of postoperative hepatic angiography on mortality after laparotomy in Grade IV/V hepatic injuries. *J Trauma Acute Care Surg.* 2018 Aug;85(2):290–297. <https://doi.org/10.1097/TA.0000000000001906>
- Moore LJ, Martin CD, Harvin JA, Wade CE, Holcomb JB. Resuscitative endovascular balloon occlusion of the aorta for control of noncompressible truncal hemorrhage in the abdomen and pelvis. *Am J Surg.* 2016 Dec;212(6):1222–1230. <https://doi.org/10.1016/j.amjsurg.2016.09.027>
- Morrison CA, Carrick MM, Norman MA et al. Hypotensive resuscitation strategy reduces transfusion requirements and severe postoperative coagulopathy in trauma patients with hemorrhagic shock: preliminary results of a randomized controlled trial. *J Trauma Inj Infect Crit Care.* 2011 Mar;70(3):652–663. <https://doi.org/10.1097/TA.0b013e31820e77ea>
- National Institute for Health and Care Excellence. 2016. Major trauma: assessment and initial management. NICE guideline [NG39]. (accessed 7 January 2019) <https://www.nice.org.uk/guidance/ng39>
- Neal MD, Hoffman MK, Cuschieri J et al. Crystalloid to packed red blood cell transfusion ratio in the massively transfused patient. *J Trauma Inj Infect Crit Care.* 2012 Apr;72(4):892–898. <https://doi.org/10.1097/TA.0b013e31823d84a7>
- Oakeshott JE, Griggs JE, Wareham GM, Lyon RM; Kent Surrey Sussex Air Ambulance Trust. Feasibility of prehospital freeze-dried plasma administration in a UK Helicopter Emergency Medical Service. *Eur J Emerg Med.* 2018 Dec 7. <https://doi.org/10.1097/MEJ.0000000000000585>
- Rago A, Duggan MJ, Marini J et al. Self-expanding foam improves survival following a lethal, exsanguinating iliac artery injury. *J Trauma Acute Care Surg.* 2014 Jul;77(1):73–77. <https://doi.org/10.1097/TA.0000000000000263>
- Remy KE, Yazer MH, Saini A et al. Effects of platelet-sparing leukocyte reduction and agitation methods on in vitro measures of hemostatic function in cold-stored whole blood. *J Trauma Acute Care Surg.* 2018; 84(6S Suppl 1): S104–s114. <https://doi.org/10.1097/ta.00000000000001870>
- Rourke C, Curry N, Khan S et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. *J Thromb Haemost.* 2012 Jul;10(7):1342–1351. <https://doi.org/10.1111/j.1538-7836.2012.04752.x>
- Sadek S, Lockey DJ, Lendrum RA, Perkins Z, Price J, Davies GE. Resuscitative endovascular balloon occlusion of the aorta (REBOA) in the pre-hospital setting: an additional resuscitation option for uncontrolled catastrophic haemorrhage. *Resuscitation.* 2016 Oct;107:135–138. <https://doi.org/10.1016/j.resuscitation.2016.06.029>
- Saito N, Matsumoto H, Yagi T et al. Evaluation of the safety and feasibility of resuscitative endovascular balloon occlusion of the aorta. *J Trauma Acute Care Surg.* 2015 May;78(5):897–904, discussion 904. <https://doi.org/10.1097/TA.0000000000000614>
- Shakur H, Roberts I, Bautista R et al; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. *Lancet.* 2010 Jul;376(9734):23–32. [https://doi.org/10.1016/S0140-6736\(10\)60835-5](https://doi.org/10.1016/S0140-6736(10)60835-5)
- Shepherd JM, Cole E, Brohi K. Contemporary patterns of multiple organ dysfunction in trauma. *Shock.* 2017 Apr;47(4):429–435. <https://doi.org/10.1097/SHK.00000000000000779>
- Smith IM, Crombie N, Bishop JR et al; RePHILL Trial Collaborators. RePHILL: protocol for a randomised controlled trial of pre-hospital blood product resuscitation for trauma. *Transfus Med.* 2018 Oct;28(5):346–356. <https://doi.org/10.1111/tme.12486>
- Smith S, White J, Wanis KN, Beckett A, McAlister VC, Hilsden R. The effectiveness of junctional tourniquets. *J Trauma Acute Care Surg.* 2019 Mar;86(3):532–539. <https://doi.org/10.1097/TA.00000000000002159>
- Sordi R, Nandra KK, Chiazza F et al. Artesunate protects against the organ injury and dysfunction induced by severe hemorrhage and resuscitation. *Ann Surg.* 2017 Feb;265(2):408–417. <https://doi.org/10.1097/SLA.0000000000001664>
- Sperry JL, Guyette FX, Brown JB et al; PAMPer Study Group. Prehospital plasma during air medical transport in trauma patients at risk for hemorrhagic shock. *N Engl J Med.* 2018 Jul 26;379(4):315–326. <https://doi.org/10.1056/NEJMoa1802345>
- Spinella PC, Cap AP. Whole blood. *Curr Opin Hematol.* 2016 Nov;23(6):536–542. <https://doi.org/10.1097/MOH.0000000000000284>
- Stanworth SJ, Davenport R, Curry N et al. Mortality from trauma haemorrhage and opportunities for improvement in transfusion practice. *Br J Surg.* 2016 Mar;103(4):357–365. <https://doi.org/10.1002/bjs.10052>
- Teixeira PGR, Brown CVR, Emigh B et al; Texas Tourniquet Study Group. Civilian prehospital tourniquet use is associated with improved survival in patients with peripheral vascular injury. *J Am Coll Surg.* 2018 May;226(5):769–776.e1. <https://doi.org/10.1016/j.jamcollsurg.2018.01.047>
- Tisherman SA, Alam HB, Rhee PM, Scalea TM, Drabek T, Forsythe RM, Kochanek PM. Development of the emergency preservation and resuscitation for cardiac arrest from trauma clinical trial. *J Trauma Acute Care Surg.* 2017 Nov;83(5):803–809. <https://doi.org/10.1097/TA.0000000000001585>

Journal of
PARAMEDIC PRACTICE

The clinical monthly for emergency care professionals

Practical guidance for your continued professional journey

Journal of Paramedic Practice (JPP) is the peer-reviewed journal delivering best practice and professional development in pre-hospital care. We provide paramedics with up-to-date clinical information, medical education and practical advice, alongside an unrivalled online CPD programme – all of which are key to unlocking your full potential.

Three easy ways to subscribe

📧 magsubscriptions.com/jpp ☎️ 0800 137 201 @ subscriptions@markallengroup.com

Online CPD not included as part of a Print Only subscription. Print Only subscription prices start from £48.00 per quarter or £192.00 per year.